keyword
MENU ▼
Read by QxMD icon Read
search

Drug pricing

keyword
https://www.readbyqxmd.com/read/28926562/generics-for-the-treatment-of-hepatitis-c-in-monoinfected-and-hiv-coinfected-patients-pros-and-cons
#1
Dario Cattaneo, Alessandro Fossati, Chiara Resnati, Massimo Galli, Cristina Gervasoni
The treatment of hepatitis C virus in monoinfected and HIV-coinfected patients has greatly changed over recent years as a result of the introduction of direct-acting antiviral agents (DAAs), which have revolutionized clinical outcomes and led to sustained virological response rates above 90-95%. The discovery of new molecules and the subsequent competition between pharmaceutical companies, together with the negotiated price policies pursued by many national health systems, have led to a gradual reduction in the cost of DAAs, and expand their use to an increasing number of patients, including those with mild liver damage...
September 19, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28921667/polysubstance-use-among-adolescents-in-a-low-income-rural-community-latent-classes-for-middle-and-high-school-students
#2
Roderick A Rose, Caroline B R Evans, Paul R Smokowski, Matthew O Howard, Katie L Stalker
PURPOSE: Rural communities are currently being impacted by a nationwide epidemic of prescription opioid misuse. Rural adolescent substance users may be at substantial risk for later addiction to these and other drugs. METHODS: This study uses Latent Class Analysis to identify subtypes of polysubstance users among a sample of 7,074 rural adolescents. Separate models were estimated for middle- and high-school youth. Predictive validity was estimated using cumulative ordinal logistic regression of the classes on a set of youth and family characteristics...
September 18, 2017: Journal of Rural Health
https://www.readbyqxmd.com/read/28918400/healthcare-resource-use-and-costs-of-severe-uncontrolled-eosinophilic-asthma-in-the-uk-general-population
#3
Marjan Kerkhof, Trung N Tran, Joan B Soriano, Sarowar Golam, Danny Gibson, Elizabeth V Hillyer, David B Price
BACKGROUND: Little is known about the prevalence of severe, uncontrolled eosinophilic asthma (SUEA) and associated costs. AIMS: We sought to determine the prevalence of SUEA and compare asthma-related healthcare resource use (HCRU) and associated costs with overall means for a general asthma population. METHODS: This cohort study evaluated anonymised medical record data (December 1989 through June 2015) from the Clinical Practice Research Datalink and the Optimum Patient Care Research Database to study UK patients with active asthma (diagnostic code and one or more drug prescriptions in the baseline year), aged 5 years and older, without concomitant COPD, and with recorded eosinophil count...
September 16, 2017: Thorax
https://www.readbyqxmd.com/read/28917469/prior-authorizations-for-dermatologic-medications-an-american-academy-of-dermatology-survey-of-us-dermatology-providers-and-staff
#4
Aaron M Secrest, Maryam M Asgari, Arianne S Kourosh, John S Barbieri, Joerg Albrecht
No abstract text is available yet for this article.
October 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28914229/clinical-effectiveness-and-cost-effectiveness-of-beta-interferon-and-glatiramer-acetate-for-treating-multiple-sclerosis-systematic-review-and-economic-evaluation
#5
G J Melendez-Torres, Peter Auguste, Xavier Armoiry, Hendramoorthy Maheswaran, Rachel Court, Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell, Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli, Hannah Fraser, Aileen Clarke
BACKGROUND: At the time of publication of the most recent National Institute for Health and Care Excellence (NICE) guidance [technology appraisal (TA) 32] in 2002 on beta-interferon (IFN-β) and glatiramer acetate (GA) for multiple sclerosis, there was insufficient evidence of their clinical effectiveness and cost-effectiveness. OBJECTIVES: To undertake (1) systematic reviews of the clinical effectiveness and cost-effectiveness of IFN-β and GA in relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS) and clinically isolated syndrome (CIS) compared with best supportive care (BSC) and each other, investigating annualised relapse rate (ARR) and time to disability progression confirmed at 3 months and 6 months and (2) cost-effectiveness assessments of disease-modifying therapies (DMTs) for CIS and RRMS compared with BSC and each other...
September 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28912143/the-relation-between-promotional-spending-on-drugs-and-their-therapeutic-gain-a-cohort-analysis
#6
Joel Lexchin
BACKGROUND: Whether drug promotion helps or hinders appropriate prescribing by physicians is debated. This study examines the most heavily promoted drugs and the therapeutic value of those drugs to help determine whether doctors should be using promotional material to inform themselves about drugs. METHODS: Lists were constructed of the 50 most heavily promoted drugs (amount of money spent on journal advertisements and visits by sales representatives) and the 50 top-selling drugs (by dollar value) for 2013, 2014 and 2015...
September 13, 2017: CMAJ Open
https://www.readbyqxmd.com/read/28910350/phylogeographic-genomic-and-meropenem-susceptibility-analysis-of-burkholderia-ubonensis
#7
Erin P Price, Derek S Sarovich, Jessica R Webb, Carina M Hall, Sierra A Jaramillo, Jason W Sahl, Mirjam Kaestli, Mark Mayo, Glenda Harrington, Anthony L Baker, Lindsay C Sidak-Loftis, Erik W Settles, Madeline Lummis, James M Schupp, John D Gillece, Apichai Tuanyok, Jeffrey Warner, Joseph D Busch, Paul Keim, Bart J Currie, David M Wagner
The bacterium Burkholderia ubonensis is commonly co-isolated from environmental specimens harbouring the melioidosis pathogen, Burkholderia pseudomallei. B. ubonensis has been reported in northern Australia and Thailand but not North America, suggesting similar geographic distribution to B. pseudomallei. Unlike most other Burkholderia cepacia complex (Bcc) species, B. ubonensis is considered non-pathogenic, although its virulence potential has not been tested. Antibiotic resistance in B. ubonensis, particularly towards drugs used to treat the most severe B...
September 14, 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28910299/access-to-benznidazole-for-chagas-disease-in-the-united-states-cautious-optimism
#8
Jonathan D Alpern, Rogelio Lopez-Velez, William M Stauffer
Drugs for neglected tropical diseases (NTD) are being excessively priced in the United States. Benznidazole, the first-line drug for Chagas disease, may become approved by the Food and Drug Administration (FDA) and manufactured by a private company in the US, thus placing it at risk of similar pricing. Chagas disease is an NTD caused by Trypanosoma cruzi; it is endemic to Latin America, infecting 8 million individuals. Human migration has changed the epidemiology causing nonendemic countries to face increased challenges in diagnosing and managing patients with Chagas disease...
September 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28910222/restricted-access-state-medicaid-coverage-of-sofosbuvir-hepatitis-c-treatment
#9
Marea B Tumber
Chronic hepatitis C (HCV) infection can persist for decades without symptoms. Many Americans are unaware of their infection status and are not receiving necessary care and treatment. This places them at greater risk for severe, even fatal, complications from the disease and increases the likelihood that they will transmit the virus to others. In late 2013, the Food and Drug Administration approved a direct acting antiviral drug called sofosbuvir to treat chronic HCV infection. Sofosbuvir is a highly effective, but very expensive, curative treatment for HCV...
January 2017: Journal of Legal Medicine
https://www.readbyqxmd.com/read/28906232/the-pharmaceutical-industry-and-the-canadian-government-folie-%C3%A3-deux
#10
Joel Lexchin
The interest of the pharmaceutical industry is in achieving a profit for its shareholders while the interest of the Canadian government should be in protecting public health. However, over the course of the past few decades the actions of the Canadian government have been tilted in favour of industry in two areas. The first is in the relationship between industry and Health Canada and is manifested in the regulation of clinical trials, the drug approval system, drug safety and promotion. The second is in economic policy as it applies to policies about patent protection, the price of medications and measures taken to incentivize research and development...
August 2017: Healthcare Policy, Politiques de Santé
https://www.readbyqxmd.com/read/28895839/ocrevus-s-role-in-ms-battle-may-signal-promising-trend
#11
Thomas Morrow
With a list price that is 25% less than a competing drug, better outcomes, and less frequent dosing, maybe Ocrevus will start a new trend: better outcomes, easier administration-and a lower price. That trifecta is great news for people managing the cost and quality of MS care.
July 2017: Managed Care
https://www.readbyqxmd.com/read/28895827/after-a-big-entrance-it-s-just-so-so-for-entresto
#12
Thomas Reinke
Some industry observers wonder why the wunderkind hasn't done more wonderfully on the market. As a brand name drug, Entresto costs substantially more than the generic ACE inhibitors and ARBs. GoodRx reports the average cash price for uninsured patients for Entresto is $504 per month, compared with $44 for enalapril.
July 2017: Managed Care
https://www.readbyqxmd.com/read/28895814/scott-gottlieb-believes-a-nimbler-speedier-fda-can-spur-competition-lower-prices
#13
Joseph Burns
The new head of the FDA might as well be starring alongside Tom Cruise in the latest installment of Mission Impossible. Since being named commissioner in May, Gottlieb has said he wants the FDA to speed the approval process for generic drugs, introduce competition to drive down prices, and get the opioid crisis under control.
August 2017: Managed Care
https://www.readbyqxmd.com/read/28895811/outcomes-based-pricing-program-puts-money-in-beneficiaries-pockets
#14
Ed Silverman
Harvard Pilgrim's program gives rebates to beneficiaries if Repatha doesn't help them avoid a heart attack or stroke. It's just the latest in a growing number of outcomes-based pricing agreements in which an insurer can get a discount from a drugmaker if a drug doesn't help patients as much as expected.
August 2017: Managed Care
https://www.readbyqxmd.com/read/28895689/a-cost-benefit-analysis-of-varicella-vaccination-in-arag%C3%A3-n
#15
Guillermo Peña Blasco, M Jesús Blasco Pérez-Aramendía
BACKGROUND: Varicella, a contagious and infectious disease that is usually benign in children, may become complicated among adults and vulnerable children and may even be life-threatening. There are effective vaccines. A retrospective study was conducted about costs and resulting hospitalizations related to this disease in the population of Aragón in the 2004-2014 period. Costs were compared to the expenses that would have been incurred if those people had received the vaccine and also to the expenses of vaccinating the 1-year-old population over the entire period...
October 1, 2017: Archivos Argentinos de Pediatría
https://www.readbyqxmd.com/read/28895227/comparing-generic-drug-markets-in-europe-and-the-united-states-prices-volumes-and-spending
#16
COMPARATIVE STUDY
Olivier J Wouters, Panos G Kanavos, Martin McKEE
Policy Points: Our study indicates that there are opportunities for cost savings in generic drug markets in Europe and the United States. Regulators should make it easier for generic drugs to reach the market. Regulators and payers should apply measures to stimulate price competition among generic drugmakers and to increase generic drug use. To meaningfully evaluate policy options, it is important to analyze historical context and understand why similar initiatives failed previously. CONTEXT: Rising drug prices are putting pressure on health care budgets...
September 2017: Milbank Quarterly
https://www.readbyqxmd.com/read/28892540/new-very-high-prices-on-old-drugs
#17
Saate Shakil, Rita F Redberg
No abstract text is available yet for this article.
September 11, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28892528/determinants-of-market-exclusivity-for-prescription-drugs-in-the-united-states
#18
Aaron S Kesselheim, Michael S Sinha, Jerry Avorn
The high prices of brand-name prescription drugs are a growing source of controversy in the United States. Manufacturers of brand-name drugs can command high prices because they are protected from generic competition by two types of government-granted monopoly rights. The first are patents on the drugs that generally define the basic period of brand-name-only sales. The second is awarded at the time of US Food and Drug Administration (FDA) approval and usually defines the minimum time until a generic can be sold...
September 11, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28892524/research-and-development-spending-to-bring-a-single-cancer-drug-to-market-and-revenues-after-approval
#19
Vinay Prasad, Sham Mailankody
Importance: A common justification for high cancer drug prices is the sizable research and development (R&D) outlay necessary to bring a drug to the US market. A recent estimate of R&D spending is $2.7 billion (2017 US dollars). However, this analysis lacks transparency and independent replication. Objective: To provide a contemporary estimate of R&D spending to develop cancer drugs. Design, Setting, and Participants: Analysis of US Securities and Exchange Commission filings for drug companies with no drugs on the US market that received approval by the US Food and Drug Administration for a cancer drug from January 1, 2006, through December 31, 2015...
September 11, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28891235/financial-arrangements-for-health-systems-in-low-income-countries-an-overview-of-systematic-reviews
#20
REVIEW
Charles S Wiysonge, Elizabeth Paulsen, Simon Lewin, Agustín Ciapponi, Cristian A Herrera, Newton Opiyo, Tomas Pantoja, Gabriel Rada, Andrew D Oxman
BACKGROUND: One target of the Sustainable Development Goals is to achieve "universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all". A fundamental concern of governments in striving for this goal is how to finance such a health system. This concern is very relevant for low-income countries. OBJECTIVES: To provide an overview of the evidence from up-to-date systematic reviews about the effects of financial arrangements for health systems in low-income countries...
September 11, 2017: Cochrane Database of Systematic Reviews
keyword
keyword
109177
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"